<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699773</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00094285</org_study_id>
    <nct_id>NCT04699773</nct_id>
  </id_info>
  <brief_title>LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)</brief_title>
  <official_title>Laser Interstitial Thermal Therapy Followed By Hypofractionated Radiation Therapy For Treatment Of Newly Diagnosed High-Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Keep Punching Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial&#xD;
      Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly&#xD;
      diagnosed gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation therapy is preferably used as an adjunct to surgery for patients with a newly&#xD;
      diagnosed or recurrent glioblastoma. LITT offers an alternative to surgical resection, and&#xD;
      due to its minimally invasive nature, does not delay initiating radiation therapy. Another&#xD;
      advantage of LITT prior to radiation therapy is the ability to obtain a tissue diagnosis of&#xD;
      the tumor prior to initiating radiation therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>The ability to complete protocol treatment (i.e. LITT and radiation therapy) without undue treatment-related acute toxicity as defined below:&#xD;
Safety: &lt; 40% rate of irreversible Grade 3 or higher neurologic treatment-related toxicity&#xD;
Early stopping rules: Two or more Grade 2 or higher symptomatic CNS hemorrhages; Eight treatment-related Grade 3 or higher non-hematologic or Grade 4 or higher hematologic treatment related toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>To describe progression-free survival rate in subjects with newly diagnosed high-grade gliomas treated with Laser Interstitial Thermal Therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>To describe median progression-free survival rate in subjects with newly diagnosed high-grade gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>To describe median progression-free survival rate in subjects with newly diagnosed high-grade gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>To describe 1- year survival rate in subjects with newly diagnosed high-grade gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>To describe overall response rate in subjects with newly diagnosed high-grade gliomas treated with Laser Interstitial Thermal Therapy followed by hypofractionated radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by M.D. Anderson Symptom Inventory</measure>
    <time_frame>2 years</time_frame>
    <description>Patient reported quality of life impact from undergoing LITT followed by hypofractionated radiation therapy using the M.D. Anderson Symptom Inventory- Brain Tumor (MDASI-BT) questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>LITT with Hypofractionated RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 25Gy/10 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LITT</intervention_name>
    <description>This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.</description>
    <arm_group_label>LITT with Hypofractionated RT</arm_group_label>
    <other_name>Laser Interstitial thermal therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiation Therapy</intervention_name>
    <description>Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.</description>
    <arm_group_label>LITT with Hypofractionated RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with radiographic evidence of suggestive of a primary high-grade glioma&#xD;
&#xD;
          2. Brain MRI with contrast demonstrates an enhancing mass within 60 days prior to&#xD;
             registration. Patient must be deemed a candidate for LITT from MRI by Neurosurgery in&#xD;
             order to be eligible.&#xD;
&#xD;
          3. History and physical including neurological exam within 30 days prior to registration&#xD;
&#xD;
          4. Karnofsky performance status ≥50% within 30 days prior to registration&#xD;
&#xD;
          5. Age ≥ 18 years old&#xD;
&#xD;
          6. Patients must have signed an approved informed consent&#xD;
&#xD;
          7. Patients with the potential for pregnancy or impregnating their partner must agree to&#xD;
             practice effective contraceptive methods to avoid conception while on study and for 6&#xD;
             months after study completion.&#xD;
&#xD;
          8. Female patients of child-bearing potential must have a negative pregnancy test within&#xD;
             28 days prior to study registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients that are not surgical candidates for stereotactic biopsy or laser ablation&#xD;
&#xD;
          2. Patients with impaired cardiac function or clinically significant cardiac diseases,&#xD;
             including any of the following:&#xD;
&#xD;
               -  History or presence of serious uncontrolled ventricular or significant&#xD;
                  arrhythmias.&#xD;
&#xD;
               -  Any of the following within 6 months prior to registration: myocardial&#xD;
                  infarction, severe/unstable angina, coronary artery bypass graft, congestive&#xD;
                  heart failure, cerebrovascular accident, transient ischemic attack , pulmonary&#xD;
                  embolism&#xD;
&#xD;
          3. Infratentorial tumor or evidence of leptomeningeal spread&#xD;
&#xD;
          4. Inability to undergo a MRI&#xD;
&#xD;
          5. Pregnant or breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Mishra, MD</last_name>
    <phone>410-328-6080</phone>
    <email>mmishra@umm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitlin Eggleston, BS</last_name>
    <phone>410-328-7586</phone>
    <email>caitlineggleston@umm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maryland Proton Treatment Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mishra, MD</last_name>
      <phone>410-328-6080</phone>
      <email>mmishra@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Eggleston, BS</last_name>
      <phone>410-328-7586</phone>
      <email>caitlineggleston@umm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Mishra, MD</last_name>
      <phone>410-328-6080</phone>
      <email>mmishra@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Eggleston, BS</last_name>
      <phone>410-328-6080</phone>
      <email>caitlineggleston@umm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCH Kaufman Cancer Center</name>
      <address>
        <city>Bel Air</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mishra, MD</last_name>
      <phone>410-328-6080</phone>
    </contact>
    <contact_backup>
      <last_name>Linda Romar</last_name>
      <email>lromar@umm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Central Maryland Radiation Oncology</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mishra, MD</last_name>
      <phone>410-328-6080</phone>
    </contact>
    <contact_backup>
      <last_name>Caitlin Eggleston</last_name>
      <email>caitlineggleston@umm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baltimore Washington Medical Center</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Mishra, MD</last_name>
      <phone>410-328-6080</phone>
      <email>mmishra@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pilar Strycula</last_name>
      <email>P.Strycula@umm.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Department of Radiation Oncology</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Laser Interstitial Thermal Therapy</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Proton Therapy</keyword>
  <keyword>Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

